Drug or treatment

Fruquintinib clinical trials

• 36Clinical trials
• 3New in 30 days
• 9Countries

Newest trials

All recruiting trials (36)

• Candonilimab with Fruquintinib and Paclitaxel Albumin-Bound as second-line treatment for advanced gastric cancer

  This phase 2 trial tests whether adding candonilimab to fruquintinib and nab-paclitaxel helps people with advanced gastric or gastroesophageal junction cancer who progressed after first-line therapy.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07920224

• Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies

  This trial tests whether combining ivarmacitinib with camrelizumab and fruquintinib can help patients with metastatic colorectal cancer who have progressed after multiple treatments.

  Recruiting Phase 2 Renmin Hospital of Wuhan University · Wuhan, Hubei · NCT07896096

• Neoadjuvant therapy for locally advanced low rectal cancer: adding fruquintinib to short-course radiotherapy with tislelizumab and CAPOX

  This study tests whether adding fruquintinib to short-course radiotherapy plus tislelizumab and CAPOX before surgery helps people with locally advanced low rectal cancer achieve a better tumor response.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07888309

• Fruquintinib plus anti-EGFR antibody for third-line metastatic colorectal cancer

  This study tests whether adding fruquintinib to cetuximab-beta helps adults with RAS wild-type metastatic colorectal cancer who have already tried and not benefited from at least two prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07724223

• Fruquintinib treatment in adults with metastatic colorectal cancer in Poland

  This study looks at whether taking fruquintinib by mouth after prior therapies helps adults with metastatic colorectal cancer in Poland live longer before the cancer progresses and overall survival, while also considering quality of life.

  Recruiting at 3 sites Takeda · Poznan, Greater Poland Voivodeship and 9 other locations · NCT07623174

• Oral Paclitaxel Plus Fruquintinib as Second-Line Treatment in Advanced Gastric/GEJ Cancer

  This trial tests whether taking an oral paclitaxel solution together with fruquintinib, chosen by the investigator, can help adults with advanced or metastatic stomach or gastroesophageal junction cancer after first-line therapy.

  Recruiting at 15 sites Harbin Medical University · Fuzhou, Fujian and 14 other locations · NCT07552402

• Fruquintinib plus nab‑paclitaxel with iparomlimab and tuvonralimab for people with advanced gastric or GEJ cancer after immunotherapy

  This trial tests whether adding fruquintinib and two immune drugs (iparomlimab and tuvonralimab) to nab‑paclitaxel helps people with advanced gastric cancer whose disease progressed after first‑line immunotherapy.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07392346

• Fruquintinib with trastuzumab and XELOX for first-line treatment of HER2‑positive advanced stomach or GEJ cancer

  This trial will try fruquintinib together with trastuzumab and XELOX to see if it helps people with HER2‑positive advanced stomach or gastroesophageal junction cancer as their first treatment.

  Recruiting Phase 1/2 Henan Cancer Hospital · Zhengzhou, Henan · NCT07334431

• Trifluridine/tipiracil plus fruquintinib versus trifluridine/tipiracil alone for metastatic oesogastric adenocarcinoma

  This will see if adding fruquintinib to trifluridine/tipiracil helps people with metastatic stomach or gastro‑oesophageal junction (G/GEJ) adenocarcinoma who have already received two or three prior treatments.

  Recruiting Phase 3 Federation Francophone de Cancerologie Digestive · Aurillac and 63 other locations · NCT07270991

• Cetuximab beta plus fruquintinib, with or without immunotherapy, for first-line treatment of RAS/BRAF wild‑type unresectable metastatic colorectal cancer

  This trial tests whether combining cetuximab beta and fruquintinib, with or without immune checkpoint inhibitors, can control cancer as a chemotherapy‑free first‑line option for patients with RAS/BRAF wild‑type unresectable metastatic colorectal cancer.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT07257653

• DSP107 plus atezolizumab versus fruquintinib for advanced colorectal cancer

  This test will see if giving DSP107 together with atezolizumab works better and is as safe as fruquintinib for adults with advanced microsatellite-stable colorectal cancer who have already tried standard treatments.

  Recruiting at 18 sites Phase 2 Kahr Medical · Aurora, Colorado and 17 other locations · NCT07235293

• Amplitude-modulated radiofrequency therapy plus fruquintinib for refractory metastatic colorectal cancer

  This trial will test whether adding amplitude-modulated radiofrequency electromagnetic fields to the drug fruquintinib helps people with metastatic colorectal cancer that has not responded to standard treatments.

  Recruiting at 9 sites Phase 2 Barbara Ann Karmanos Cancer Institute · Bay City, Michigan and 8 other locations · NCT07130903

• Prognostic Factors for Fruquintinib in Metastatic Colorectal Cancer

  This cohort study tests how clinical and biological factors relate to survival outcomes in adults with metastatic colorectal cancer treated with fruquintinib.

  Recruiting at 83 sites Federation Francophone de Cancerologie Digestive · Poitiers, France and 82 other locations · NCT07124858

• 5‑Fluorouracil–based chemotherapy plus fruquintinib for advanced or metastatic colorectal cancer

  This phase II test will combine 5‑FU–based chemotherapy with the oral drug fruquintinib as a first-line treatment for adults with locally advanced unresectable or metastatic colorectal cancer.

  Recruiting Phase 2 The Methodist Hospital Research Institute · Houston, Texas · NCT07042685

• Monitoring Fruzaqla treatment in adults with metastatic colorectal cancer in South Korea

  This project will track side effects, including serious ones, in adults in South Korea who are being treated with Fruzaqla (fruquintinib) for metastatic colorectal cancer.

  Recruiting Takeda · Seoul · NCT07035886

• Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer

  This study will test whether adding fruquintinib to FOLFIRI helps people with metastatic colorectal cancer who progressed after first-line FOLFOX plus bevacizumab.

  Recruiting at 14 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 13 other locations · NCT07011576

• Fruquintinib with or without TAS-102 for refractory metastatic colorectal cancer

  This trial tests whether adding TAS-102 (Lonsurf) to fruquintinib helps people with microsatellite-stable, advanced or metastatic colorectal cancer that no longer responds to standard chemotherapy.

  Recruiting at 13 sites Phase 2 Criterium, Inc. · New Haven, Connecticut and 12 other locations · NCT06992258

• Evaluating a new treatment for advanced colorectal cancer

  This study is testing a new combination treatment for advanced colorectal cancer to see if it can help patients who haven't had success with other therapies.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT06979908

• Fruquintinib plus tislelizumab versus trifluridine/tipiracil plus bevacizumab for MSS/pMMR metastatic colorectal cancer without active liver metastases

  This trial tests whether combining fruquintinib with tislelizumab works better than trifluridine/tipiracil plus bevacizumab for adults with MSS/pMMR metastatic colorectal cancer who do not have active liver metastases.

  Recruiting at 15 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Linz and 22 other locations · NCT06856837

• Neoadjuvant treatment for gastric cancer using Envafolimab and Fruquintinib with chemotherapy

  This study is testing if a new combination of Envafolimab, Fruquintinib, and chemotherapy can help people with locally advanced gastric cancer do better before surgery.

  Recruiting Phase 2 First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06791083

• Evaluating Fruquintinib for Metastatic Colorectal Cancer

  This study is testing how well Fruquintinib works for people with metastatic colorectal cancer who have already tried other treatments, to see how it affects their survival and quality of life.

  Recruiting at 42 sites iOMEDICO AG · Biberach, Baden-Wurttemberg and 41 other locations · NCT06787105

• Combining Fruquintinib with chemotherapy for treating gastric cancer after surgery

  This study is testing if adding Fruquintinib to standard chemotherapy can help people with HER2-negative gastric cancer who had surgery and are at high risk of their cancer coming back.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou · NCT06774222

• Combining Fruquintinib, Chidamide, and Sintilimab for Advanced Colorectal Cancer Treatment

  This study is testing a new combination of three drugs to see if it can help people with advanced colorectal cancer that hasn't improved with other treatments.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT06685276

• Combining Fruquintinib and Tislelizumab with Radiotherapy for Esophageal Cancer

  This study is testing if combining two new cancer treatments, Fruquintinib and Tislelizumab, with radiation can help people with advanced esophageal cancer feel better and improve their outcomes.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT06646588

• Combining Fruquintinib, Adebrelimab, and Radiotherapy for Advanced Colorectal Cancer

  This study is testing a new treatment that combines Fruquintinib, Adebrelimab, and radiotherapy to see if it can help people with advanced colorectal cancer who haven't responded to other treatments.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT06613113

• Combining fruquintinib and sintilimab for advanced endometrial cancer treatment

  This study is testing if a new combination of fruquintinib and sintilimab can help people with advanced endometrial cancer who didn't respond to their first treatment feel better compared to standard chemotherapy.

  Recruiting at 3 sites Phase 3 Hutchmed · Beijing, Beijing Municipality and 16 other locations · NCT06584032

• Evaluating fruquintinib's safety in minority groups with advanced colorectal cancer

  This study is testing if fruquintinib is safe for Black and Hispanic adults with advanced colorectal cancer who have already had treatment.

  Recruiting at 32 sites Phase 4 Takeda · Birmingham, Alabama and 44 other locations · NCT06562543

• Fruquintinib and pirfenidone with an anti-PD-1 antibody in advanced colorectal cancer

  This study tests whether adding fruquintinib and pirfenidone to an anti-PD-1 therapy helps people with advanced colorectal cancer that has not responded to standard treatments.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06484153

• Fruquintinib treatment for advanced liver cancer after immunotherapy

  This study is testing if a new drug called fruquintinib can help people with advanced liver cancer who haven't responded well to previous immunotherapy treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06446154

• Combining fruquintinib with HAI-FOLFOX for treating refractory colorectal cancer

  This study tests whether combining a new drug called fruquintinib with a specific chemotherapy method can help people with colorectal cancer that hasn't responded to other treatments live longer and feel better.

  Recruiting Phase 2/3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06441565

• Combining fruquintinib and albumin-paclitaxel with or without PD-1 antibody for advanced gastric cancer treatment

  This study is testing if combining fruquintinib and albumin-paclitaxel, with or without a PD-1 antibody, can help people with advanced gastric cancer who have already had other treatments.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06417892

• Combining Fruquintinib, Regorafenib, and Sintilimab with Radiotherapy for Advanced Colorectal Cancer

  This study is testing a new combination of three cancer drugs with or without radiation to see if it helps people with advanced colorectal cancer who have already tried other treatments.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06356584

• Combination treatment for advanced gastric cancer

  This study is testing a new combination of treatments for people with advanced stomach cancer to see if it can help improve their health and fight the disease better.

  Recruiting Phase 1/2 Henan Cancer Hospital · Zhengzhou, Henan · NCT06329973

• Short-course radiotherapy with Fruquintinib and Adebrelimab for advanced rectal cancer

  This study is testing a new treatment plan that combines short radiation therapy with Fruquintinib and Adebrelimab for people with advanced rectal cancer to see if it helps them better than current methods.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan · NCT06234007

• Combining Cadonilimab, Fruquintinib, and SBRT for Advanced Colorectal Cancer Treatment

  This study is testing a new combination of treatments for people with advanced colorectal cancer who haven't responded to previous therapies to see if it can help them feel better.

  Recruiting Phase 2 Huazhong University of Science and Technology · Wuhan, Hubei · NCT06168786

• Third-line fruquintinib plus serplulimab for advanced metastatic colorectal cancer without liver-only metastases

  This tests whether combining fruquintinib and serplulimab helps people with microsatellite-stable metastatic colorectal cancer who have already failed standard treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT05954429

Quick answers

How many clinical trials of Fruquintinib are recruiting right now?

36, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 9 countries. The most sites are in China (24 trials), United States (6 trials), Germany (3 trials), France (2 trials), Poland (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 23, Phase 1/2: 2, Phase 3: 2, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →